Lividomycin Therapy in Intestinal Infectious Diseases with Special Reference to the Combination Use with AB-PC

Abstract

It was reported at the 21st medical meeting of Eastern Japan Section of Japanese Association for Infectious Diseases that Lividomycin (LVM), a newly developed broad spectrum antibiotic, is as powerful as KM in clinical use as well as antimicrobial activity in bacillary dysentery.
In this paper, the results of clinical application of LVM in both single use and the combination use with AB-PC were reported. Along with our view on antibiotic usage that the combination use of easily and poorly absorbable drugs must be advantageous to the single use in the treatment of most intestinal infectious diseases, the main emphasis was put on the comparison between the data obtained by the both methods.
Subjected were the patients of bacillary dysentery, vibrio parahaemolyticus infection, salmonellosis, and acute colitis negative of known pathogens, all of whom acute colitis negative of known pathogens, all of whom were those treated at Tokyo Metropolitan Ebara Hospital, recently.
Dosis of LVM was: uniformly 2.0g per day (0.5g every 6 hours orally) in the single use; 1.0 g LVM and 1.0g AB-PC (divided into every 6 hours dosis, likewise) in the combination use; medication span was uniformly 5 days.
Diarrheal frequency and stool appearance were taken up as markers of clinical effectiveness in acute stage and bacillary discharge rate was another marker especially in carrier state. The clinical effectiveness was categorized here as excellent, good and poor.
The summary: In bacillary dysentery: clinical effectiveness; four excellent, 7 good, 2 poor in 13 cases of the single use; 2 excellent, 3 good, 0 poor in the combination use. Stoppage of bacillary discharge was seen at 4th day in the combination use and 5th day in the single use at the longest.
In vibrio parahaemolyticus infection: clinical effectiveness; 5 excellent, 4 good, 0 poor in 9 cases of the single use; 7 excellent, 1 good, 0 poor in the combination use. The stoppage rate of bacillary discharge was almost equal in the both.
In salmonellosis: only the single use was applied to four symptomatic cases and recovery was slower than expected. The combination use was applied to the carriers, in that, bacillary redischarge was seen in 44.4%(4 out of 9 cases).
In acute colitis negative of known pathogens: clinical effectiveness; 2 excellent, 2 good, 3 poor in 6 cases of the single use; 3 excellent, 4 good, 2 poor in 9 cases of the combination use.
From above results, it is our impression that the combination use is given a position, if not much, but recognizably superior to the single use except for in salmonellosis where neither single nor combination use could yield satisfactory effects and some other medication methods should be devised.